Loading quotes...
Forecast
The analysts' average price target is €73.31 (+19.98%). The median is €73.31 (+19.98%).
| Buy |
Â
11 |
| Hold |
Â
1 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
TG Therapeutics raises revenue outlook, BRIUMVI gains market share in RMS
TG Therapeutics reports strong commercial growth of BRIUMVI in relapsing multiple sclerosis and raises its 2024 revenue guidance to $890–905 million; the company is targeting a $1 billion run rate by the end of Q4. BRIUMVI has captured more than one-third of the IV anti‑CD20 market, a simplified IV dosing regimen should ease use, and a sBLA is upcoming. A subcutaneous formulation showed about 60% bioavailability in Phase I and will be tested in Phase III against two dosing intervals; TG sees broad potential also in myasthenia gravis and treatment‑resistant schizophrenia. » More on de.investing.com
TG Therapeutics stock recovers despite earnings miss
TG Therapeutics shares rose intraday by 5.9%, extending the recovery after the sharp sell-off following the Q2 results. The company reported EPS of $0.05 versus a consensus of about $0.44; the miss was due to higher manufacturing and operating costs, not weak revenue. Revenue increased in the second quarter to roughly $240 million (+70% YoY) and the full-year guide was raised to about $950 million; additionally, the completed enrollment of the phase-3 trial for subcutaneous BRIUMVI administration could be another catalyst. » More on de.investing.com
TG Therapeutics climbs after Briumvi outperforms expectations and positive subcutaneous data
ClearBridge's Q2 investor letter named TG Therapeutics as a top contributor after its key drug Briumvi delivered greater-than-expected growth and positive clinical results for a subcutaneous formulation that could expand the addressable market. The stock has risen sharply over the past month and year, reflecting renewed investor interest in the company's commercial-stage multiple sclerosis franchise. » More on finance.yahoo.com
TG Therapeutics hits 52-week high at $57.40
Shares of TG Therapeutics rose to a 52-week high of $57.40 and are up about 86% year-to-date, bringing market capitalization to $8.09 billion. InvestingPro currently rates the stock as undervalued compared with its fair value. For Q1 2026 the company missed EPS expectations ($0.12 vs. $0.28) and reported slightly lower revenue of $194.8 million. TG Therapeutics is simultaneously advancing clinical programs with Briumvi, including initiated Phase 2 studies in treatment‑resistant schizophrenia and myasthenia gravis, positive post‑hoc Phase 3 data, and a successful ENHANCE study endpoint demonstrating bioequivalence of a new single‑dose infusion regimen. » More on de.investing.com
TG Therapeutics reaches 52-week high at 54.04 USD
Shares of TG Therapeutics rose to a 52-week high of 54.04 USD, giving the company a market capitalization of about 7.57 billion USD; the stock is up 72.76% year-to-date and gained 52.54% over the past year. Despite the share price increase, the company missed Q1 2026 estimates with EPS of 0.12 USD (expectation 0.28 USD) and revenue of 194.8 million USD (forecast 199.45 million USD). TG Therapeutics also reported progress with BRIUMVI: start of a phase-2 maintenance study in myasthenia gravis, positive phase-1 topline data and positive post-hoc results, and a successful ENHANCE bioequivalence study in multiple sclerosis. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 229.48M | 66.54% |
| Gross profit | 192.34M | 69.00% |
| Net profit | 48.97M | 85.30% |
| EBITDA | 79.24M | 184.44% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €8.64B |
Number of shares | 151.15M |
52-week high/low | €61.96 - €24.37 |
| Dividends | No |
Beta | 1.81 |
P/E ratio | 84.25 |
PEG ratio | -1.11 |
P/B ratio | 15.44 |
P/S ratio | 10.57 |
Company profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
| Name | TG Therapeutics |
| CEO | Michael S. Weiss |
| Headquarters | Morrisville,
ny USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 05/03/2010 |
| Employees | 399 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | TGTX |
London Stock Exchange | 0VGI.L |
Frankfurt | NKB2.F |
DĂĽsseldorf | NKB2.DU |
London | 0VGI.L |
SIX | NKB2.SW |
MĂĽnchen | NKB2.MU |